Loading...
Market
Which company will launch the first competitor to Mounjaro in HK by end of 2025?
2
Resolution / Starting Odds
Novo Nordisk • 25%
Pfizer • 25%
Sanofi • 25%
Other • 25%
Official announcements from pharmaceutical companies or Hong Kong health authorities
Story
Eli Lilly Gets Hong Kong Approval to Launch Mounjaro, First Weight-Loss Drug in China Region
Oct 28, 2024, 01:17 AM
Eli Lilly & Co. is set to launch its blockbuster weight-loss drug Mounjaro in Hong Kong by the end of this year, following approval from the Hong Kong government, Bloomberg News reported. Mounjaro, also known as tirzepatide, is approved for weight management and type 2 diabetes. This launch will make Mounjaro the first weight-loss drug available for sale in the China region, potentially tapping into a significant market across the border. The drug will be available in Kwikpen form.
View original story
Similar markets
Meta • 25%
Apple • 25%
Microsoft • 25%
Other • 25%
OpenAI • 25%
Google • 25%
Microsoft • 25%
Other • 25%
Apple • 25%
Microsoft • 25%
Amazon • 25%
No Major Response • 25%
Corel • 25%
Autodesk • 25%
Affinity • 25%
Other • 25%
Anthropic • 25%
Microsoft • 25%
Amazon • 25%
Other • 25%
Binance • 25%
Coinbase • 25%
Kraken • 25%
Other • 25%
Henderson Land • 25%
New World Development • 25%
Cheung Kong Holdings • 25%
Other • 25%
Epic Games • 25%
Match Group • 25%
Amazon • 25%
Other • 25%
